Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important

Jin, Xi-Feng; Spampatti, Matilde Pia; Spitzweg, Christine; Auernhammer, Christoph J.

doi:10.1007/s11154-018-9443-6

Cited by 25 publications

(20 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In 2010, they were classified by WHO as malignant neoplasms [2]. NENs are divided into two categories: well-differentiated neoplasms, i.e., neuroendocrine tumors (NETs), and poorly-differentiated NENs called neuroendocrine cancers (NECs) [3]. In recent decades, the number of gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) cases has been increasing, but it seems to be associated with the progress in diagnostics.…”

Section: Introductionmentioning

confidence: 99%

“…GEP-NETs are the second most frequent type of neoplasm of the gastrointestinal tract, just after colorectal cancer [5]. NETs present a heterogeneous group of malignancies; very diverse in terms of their clinical and biological properties [3]. The functional gastro-entero-pancreatic NETs (hormonally active GEP-NETs) include small bowel NETs (ileum and jejunum), which can produce serotonin, and maybe accompanied by a carcinoid syndrome.…”

Section: Introductionmentioning

confidence: 99%

“…Functional pancreatic neuroendocrine tumors (f-pNETs) are able to produce gastrin, insulin, intestinal polypeptides and glucagon, and can lead to the occurrence of such clinical syndromes as ulcers, hypoglycemia, hyperglycemia and diarrhea [6]. Rare p-NETs like glucagonoma and VIPoma are associated with hypokalemia and watery diarrhea, but less frequently [3]. Otherwise, non-functional pNETs (nf-pNETs) can still secrete some amounts of peptides or amines, but the levels are so low that they do not cause symptoms or are metabolically inactive [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms

et al. 2020

View full text Add to dashboard Cite

Introduction: In recent decades, the number of gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) cases, associated with coexisting metabolic disorders, has been continuously increasing. Patients with progressing neoplastic disease are at a risk of malnutrition. To improve the quality of life of neuroendocrine neoplasms (NEN) patients, the therapeutic approach should be supported by a well-balanced diet. The aim of the study was to analyze the nutritional errors and deficits in a group of GEP-NET patients. Materials and methods: The study group included 26 GEP-NET patients; 13 men and 13 women. The mean age of women was 68.77 ± 8.0, and the mean age of men was 64.69 ± 8.1. Three interviews on consumption in the last 24 h were performed, in order to evaluate the quality and quantity of nutrition. The data was incorporated into a dietetics software, which allows one to calculate the number of over 58 micronutrients and macronutrients with the participation of 52 menus. Subsequently, the mean values were compared with the current nutritional standards. Results: An energy deficit was observed in the group of women—76.9%, and men—100%, as well as high fat consumption in 23.1% in both groups. The proportions of SFA/MUFA/PUFA were very negative, whereas the consumption of saccharose was too high. Vitamin D deficiency was observed in 100% of men and women. Moreover, both men and women experienced the deficiency of vitamin E, folates and niacin. The consumption of sodium and phosphorus was twice as high as recommended, and an insufficient supply of calcium was observed in 80% of women and 90% of men. The insufficient consumption of magnesium, iodine and potassium in a significant part of the studied group was observed. All participants consumed too much cholesterol and insufficient amounts of fiber. The healthy diet indicator (HDI) and diet quality index (DQI) scores were 3.1 ± 1.8 (HDI) and 3.7 ± 1.6 (DQI) for women, and 7.2 ± 2.6 (HDI) and 8.5 ± 2.4 (DQI) for men. Conclusions: When analyzing the nutrition of GEP-NET patients, we highlight that they do not have a proper diet, despite the fact that they changed the way they eat. Dietetics support and the development of official nutritional standards seem to be a necessary element in the therapy of GEP-NET patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Apart from them, supportive therapy cannot be ignored debulking surgery and interventional radiologic techniques to reduce tumors bulk or load, as well as systemic medical treatment options to manage or prevent hypersecretion syndromes and treatment-related side effects. What's more, supportive therapy also encompasses psychosocial support, expert nursing, nutritional support, and management of cancerrelated pain [26,27].…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Features and Prognosis of Gastric Neuroendocrine Neoplasms

Wang

Wen

Tian

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Purpose: We performed a retrospective study to investigate the relationship between clinicopathological features and prognosis of G-NEN.Methods: Clinicopathological features and follow-up data of 67 patients with G-NEN treated at Shandong Provincial Hospital affiliated of Shandong University were analyzed retrospectively. Results: This whole cohort included 53 males and 14 females, with a mean age of 59.37±9.80 years. The clinical symptoms and the primary tumor site were not specific. Neuroendocrine tumor, neuroendocrine carcinoma, and mixed neuroendocrine–non‐neuroendocrine neoplasm accounted for 14.93%, 59.70%, and 25.37%, respectively. TNM stages Ⅰ-Ⅳ: 6, 6, 49, 4, respectively. All patients underwent surgically treated. Forty-five patients underwent laparoscopic surgery, and twenty-two patients received an open approach. The median survival time was 36 months in all patients. The overall survival rate for the entire cohort was 68.1 %, 44.7 %, and 34.5% at 1, 3, and 5 years, respectively. Logistic regression analysis revealed that the invasive depth of tumors was predictors for metastasis. The univariate analysis confirmed that smoking, T stage, distant metastasis, and surgical method were related to survival. COX regression analysis showed that the T stage (HR=4.817, 95%CI: 1.021-22.729, P=0.047) was an independent risk factor for evaluating the prognosis of patients with G-NEN.Conclusions: G-NEN is a kind of rare tumors that can occur at any part of the stomach. The clinical features are not specific. The tumor invasive depth related to tumor metastasis. The prognosis is associated with smoking, T stage, distant metastasis, and surgical method. Of them, T stage is an independent prognostic factor for G-NEN patients. But larger studies are needed in the future.

show abstract

“…If the decision is made to perform surgery on a patient with NEN, a multidisciplinary team should discuss the perioperative proceedings including an effective prophylaxis against an intraoperative carcinoid crisis, supportive therapy, and nutrition [7,8,22]. Psychosocial support, expert nursing, nutritional support and management of cancer related pain will be reviewed by the groups, Auernhammer and Spitzweg, as well as the group, Faggiano, Colao, Muscogiuri and colleagues [23,24].…”

mentioning

confidence: 99%

Neuroendocrine neoplasms – think about it and choose the most appropriate diagnostic and therapeutic steps

Koch

Petersenn

2018

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important

Cited by 25 publications

References 137 publications

Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms

Assessment and State of Nutrition of Patients with Gastroenteropancreatic Neuroendocrine Neoplasms

Clinicopathological Features and Prognosis of Gastric Neuroendocrine Neoplasms

Neuroendocrine neoplasms – think about it and choose the most appropriate diagnostic and therapeutic steps

Contact Info

Product

Resources

About